Mark Parry has worked with Intertek Melbourn for almost 20 years after graduating from Cambridge University and currently works as the Technical Director. Mark has worked in a range of pharmaceutical analysis and formulation development areas with a particular focus on inhaled and nasal drug products.
Mostly working in the pre-approval stages, Mark’s background includes extensive experience with product and formulation development, as well as method development and validation, stability studies, and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry.
Mark currently works as the Technical Director, supporting the wide range of analytical, formulation and product development activities across the company.
Inhaled and nasal delivery platforms have specific applications outside of their traditional uses for asthma/chronic obstructive pulmonary disease (COPD) and seasonal rhinitis/sinusitis: They can offer real advantages for the delivery of therapeutic biologics.